Literature DB >> 12559180

Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas.

Yuichi Kitagawa1, Trisha A Unger1, Shari Taylor2, Richard A Kozarek1, L William Traverso3.   

Abstract

The aim of our study was to examine the case histories of patients with intraductal papillary mucinous tumor (IPMT) treated with resection to determine predictors of prognosis. Between 1989 and 2000, all patients treated with pancreatic resection for IPMT (n = 63) were analyzed. The diagnosis of IPMT was made using the surgical specimen and the World Health Organization definition. Predictors were determined using univariate and multivariate analysis. The pathologic findings were benign (n = 30), carcinoma in situ (CIS; n = 5), and invasive carcinoma (n = 28). After univariate analysis, predictors of malignancy (invasive plus CIS) were jaundice (odds ratio = 10.32), elevated serum CA19-9 (odds ratio = 15.0), any abnormal liver function test (odds ratio = 7.69), and p53 overexpression. The only predictor of benign disease was gross mucus observed during endoscopy (odds ratio = 4.35). After multivariate analysis, predictors of malignancy were any abnormal liver function test (odds ratio = 5.09) and p53 overexpression, whereas the only predictor of benign disease was still gross mucus (odds ratio = 5.88). Actuarial 3- and 5-year survival for benign disease was 95% and 83% and for malignant disease 52% and 44%, respectively (P = 0.0048). Survival curves also favored p53-negative tumors vs. p53-positive tumors (P = 0.0055). In the 33 patients with malignant disease (mean follow-up time = 35 months), the presence of gross mucus was a predictor of prolonged survival after univariate and multivariate analysis (odds ratio = 4.34 and 4.55, respectively), whereas alcohol abuse was a predictor of poor survival (odds ratio = 3.41 and 3.60, respectively). Gross mucus observed during endoscopy is a predictor of benign IPMT and, within the group with malignant IPMT; the presence of gross mucus was associated with better survival. Survival was also strongly associated with either benign IPMT or negative staining for p53 overexpression. Copyright 2003 The Society for Surgery of the Alimentary Tract, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559180     DOI: 10.1016/S1091-255X(02)00152-X

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  24 in total

1.  Intraductal papillary mucinous tumors of the pancreas: thin-section helical CT findings.

Authors:  Y Fukukura; F Fujiyoshi; M Sasaki; H Inoue; S Yonezawa; M Nakajo
Journal:  AJR Am J Roentgenol       Date:  2000-02       Impact factor: 3.959

2.  HASTE MR cholangiopancreatography in the evaluation of intraductal papillary-mucinous tumors of the pancreas.

Authors:  Y Fukukura; F Fujiyoshi; M Sasaki; N Ichinari; H Inoue; Y Kajiya; M Nakajo
Journal:  J Comput Assist Tomogr       Date:  1999 Mar-Apr       Impact factor: 1.826

3.  MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas.

Authors:  H Irie; H Honda; H Aibe; T Kuroiwa; K Yoshimitsu; K Shinozaki; K Yamaguchi; M Shimada; K Masuda
Journal:  AJR Am J Roentgenol       Date:  2000-05       Impact factor: 3.959

4.  Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas.

Authors:  K Z'graggen; J A Rivera; C C Compton; M Pins; J Werner; C Fernández-del Castillo; D W Rattner; K B Lewandrowski; A K Rustgi; A L Warshaw
Journal:  Ann Surg       Date:  1997-10       Impact factor: 12.969

5.  Diagnosis of mucin-producing tumor of the pancreas with an intraductal ultrasonographic system.

Authors:  T Taki; H Goto; Y Naitoh; Y Hirooka; T Furukawa; T Hayakawa
Journal:  J Ultrasound Med       Date:  1997-01       Impact factor: 2.153

6.  [Clinicopathological and diagnostic study of mucin producing pancreatic tumors].

Authors:  H Maguchi
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1994-05

7.  Intraductal papillary mucinous neoplasms of the pancreas associated with so-called "mucinous ductal ectasia". Histochemical and immunohistochemical analysis of 29 cases.

Authors:  E Nagai; T Ueki; K Chijiiwa; M Tanaka; M Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  1995-05       Impact factor: 6.394

Review 8.  Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms.

Authors:  Y M Shyr; C H Su; S H Tsay; W Y Lui
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

9.  Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.

Authors:  F Sessa; E Solcia; C Capella; M Bonato; A Scarpa; G Zamboni; N S Pellegata; G N Ranzani; F Rickaert; G Klöppel
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

10.  Intraductal papillary-mucinous neoplasm of the pancreas: a report of five cases with immunohistochemical findings.

Authors:  J G Kench; R P Eckstein; R C Smith
Journal:  Pathology       Date:  1997-02       Impact factor: 5.306

View more
  39 in total

1.  Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation.

Authors:  Anne Couvelard; Alain Sauvanet; Reza Kianmanesh; Pascal Hammel; Nathalie Colnot; Philippe Lévy; Philippe Ruszniewski; Pierre Bedossa; Jacques Belghiti
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

Review 2.  [Cystic lesions of the pancreas].

Authors:  B Buerke; C Schülke
Journal:  Radiologe       Date:  2015-02       Impact factor: 0.635

Review 3.  Endoscopic ultrasound advances, part 1: diagnosis.

Authors:  Edward Kim; Jennifer J Telford
Journal:  Can J Gastroenterol       Date:  2009-09       Impact factor: 3.522

Review 4.  Ultrasonographic findings and natural history of intraductal papillary-mucinous neoplasms of the pancreas.

Authors:  Go Kobayashi; Naotaka Fujita; Yutaka Noda; Takashi Obana; Osamu Takasawa
Journal:  J Med Ultrason (2001)       Date:  2008-09-19       Impact factor: 1.314

5.  Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Atsushi Kanno; Kennichi Satoh; Morihisa Hirota; Shin Hamada; Jun Umino; Hiromichi Itoh; Atsushi Masamune; Tohru Asakura; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2010-04-10       Impact factor: 7.527

6.  Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection.

Authors:  Roberto Salvia; Carlos Fernández-del Castillo; Claudio Bassi; Sarah P Thayer; Massimo Falconi; William Mantovani; Paolo Pederzoli; Andrew L Warshaw
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

7.  Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors.

Authors:  Madhava Pai; Nagy Habib; Hakan Senturk; Sundeep Lakhtakia; Nageshwar Reddy; Vito R Cicinnati; Iyad Kaba; Susanne Beckebaum; Panagiotis Drymousis; Michel Kahaleh; William Brugge
Journal:  World J Gastrointest Surg       Date:  2015-04-27

8.  Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis.

Authors:  Edward S Huang; G Scott Gazelle; Chin Hur
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

Review 9.  Management of mucin-producing cystic neoplasms of the pancreas.

Authors:  Stefan Fritz; Andrew L Warshaw; Sarah P Thayer
Journal:  Oncologist       Date:  2009-02-11

10.  The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN.

Authors:  Rachel E Simpson; Eugene P Ceppa; Howard H Wu; Fatih Akisik; Michael G House; Nicholas J Zyromski; Attila Nakeeb; Mohammad A Al-Haddad; John M DeWitt; Stuart Sherman; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2019-01-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.